16-week Flexible vs. 8-week Semaglutide Titration
Mo kle
Abstrè
Dat
| Dènye verifye: | 05/31/2020 |
| Premye Soumèt: | 06/16/2020 |
| Enskripsyon Estimasyon Soumèt: | 06/23/2020 |
| Premye afiche: | 06/24/2020 |
| Dènye Mizajou Soumèt: | 06/23/2020 |
| Dènye Mizajou afiche: | 06/24/2020 |
| Dat aktyèl kòmanse etid la: | 02/22/2020 |
| Dat Estimasyon Prensipal Estimasyon an: | 05/09/2022 |
| Dat estime fini etid la: | 09/09/2022 |
Kondisyon oswa maladi
Entèvansyon / tretman
Drug: Slow semaglutide titration
Other: label recommended titration
Faz
Gwoup bra
| Bra | Entèvansyon / tretman |
|---|---|
| Active Comparator: label recommended titration eight-week titration regimen as recommended in by the product label (0.25mg/week for 4 weeks, 0.5mg/week for 4 weeks, 1mg/week for the remainder of the therapy) | Other: label recommended titration label recommended titration |
| Experimental: Slow semaglutide titration A slower 16-week titration regimen (initiate treatment at 0.0675mg/week and increase the dose by 0.0675mg weekly until a dose of 1mg/week is reached) | Drug: Slow semaglutide titration Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration) |
Kritè kalifikasyon yo
| Laj ki kalifye pou etid | 18 Years Pou 18 Years |
| Sèks ki kalifye pou etid | All |
| Aksepte Volontè Healthy | Wi |
| Kritè | Inclusion Criteria: - Have personally signed and dated the informed consent form indicating that he/she has been informed of all pertinent aspects of the trial. - Be willing and able to comply with the scheduled visits and other study procedures. - Meet one of the following categories: 1. The subject is a male. 2. The subject is a female who is not of reproductive potential, defined as a female who either: (1) is postmenopausal (defined as at least 12 months with no menses in women ≥45 years of age); (2) has had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR (3) has a congenital or acquired condition that prevents childbearing. 3. The subject is a female who is of reproductive potential and agrees to avoid becoming pregnant: while receiving study drug and for 60 days after the last dose of study drug by complying with one of the following: (1) practice abstinence† from heterosexual activity OR (2) use (or have her partner use) acceptable contraception during heterosexual activity. Acceptable methods of contraception are‡: Single method (one of the following is acceptable): - non-hormonal intrauterine device (IUD) - vasectomy of a female subject's male partner Combination method (requires use of two of the following): - diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide) - cervical cap with spermicide (nulliparous women only) - contraceptive sponge (nulliparous women only) - male condom or female condom (cannot be used together) Exclusion Criteria: - Has a known contraindication to use of GLP-1 agonists. - Has been treated with a GLP-1 agonist in the last 30 days. - Has a history of type 1 diabetes mellitus - Has a medical history of untreated active proliferative retinopathy. - Has other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or blinded investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial. |
Rezilta
Mezi Rezilta Prensipal yo
1. Gastrointestinal adverse events (GI-AEs) [16 weeks - from visit one to visit seven (and in each visit alone)]
